Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety.
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
received:
13
07
2022
accepted:
12
10
2022
medline:
29
6
2023
pubmed:
31
1
2023
entrez:
30
1
2023
Statut:
ppublish
Résumé
The objective of this study was to assess the durability, short-term and long-term effectiveness, and safety of tofacitinib in ulcerative colitis (UC) in clinical practice. This is a retrospective multicenter study including patients with UC who had received the first tofacitinib dose at least 8 weeks before the inclusion. Clinical effectiveness was based on partial Mayo score. A total of 408 patients were included. Of them, 184 (45%) withdrew tofacitinib during follow-up (mean = 18 months). The probability of maintaining tofacitinib was 67% at 6 m, 58% at 12 m, and 49% at 24 m. The main reason for tofacitinib withdrawal was primary nonresponse (44%). Older age at the start of tofacitinib and a higher severity of clinical activity were associated with tofacitinib withdrawal. The proportion of patients in remission was 38% at week 4, 45% at week 8, and 47% at week 16. Having moderate-to-severe vs mild disease activity at baseline and older age at tofacitinib start were associated with a lower and higher likelihood of remission at week 8, respectively. Of 171 patients in remission at week 8, 83 (49%) relapsed. The probability of maintaining response was 66% at 6 m and 54% at 12 m. There were 93 adverse events related to tofacitinib treatment (including 2 pulmonary thromboembolisms [in patients with risk factors] and 2 peripheral vascular thrombosis), and 29 led to tofacitinib discontinuation. Tofacitinib is effective in both short-term and long-term in patients with UC. The safety profile is similar to that previously reported.
Identifiants
pubmed: 36716287
doi: 10.14309/ajg.0000000000002145
pii: 00000434-202307000-00024
doi:
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1237-1247Informations de copyright
Copyright © 2023 by The American College of Gastroenterology.
Références
Raine T, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: Medical treatment. J Crohns Colitis 2022;16(1):2–17.
Spinelli A, Bonovas S, Burisch J, et al. ECCO guidelines on therapeutics in ulcerative colitis: Surgical treatment. J Crohns Colitis 2022;16(2):179–89.
Chaparro M, Garre A, Ricart E, et al. Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: Results from the ENEIDA registry. Aliment Pharmacol Ther 2018;48(8):839–51.
Gisbert JP, Chaparro M. Predictors of primary response to biologic treatment [anti-TNF, vedolizumab, and ustekinumab] in patients with inflammatory bowel disease: From basic science to clinical practice. J Crohns Colitis 2020;14(5):694–709.
Taxonera C, Iglesias E, Muñoz F, et al. Adalimumab maintenance treatment in ulcerative colitis: Outcomes by prior anti-TNF use and efficacy of dose escalation. Dig Dis Sci 2017;62(2):481–90.
Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in crohn's disease: A review. Am J Gastroenterol 2009;104(3):760–7.
Chaparro M, Andreu M, Barreiro-de Acosta M, et al. Effectiveness of infliximab after adalimumab failure in Crohn's disease. World J Gastroenterol 2012;18(37):5219–24.
Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012;18(11):2026–33.
Chaparro M, Panes J, García V, et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose “escalation” in patients losing response. J Clin Gastroenterol 2011;45(2):113–8.
Chaparro M, Panés J, García V, et al. Long-term durability of response to adalimumab in Crohn's disease. Inflamm Bowel Dis 2012;18(4):685–90.
Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med 2012;367(7):616–24.
Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. New Engl J Med 2017;376(18):1723–36.
Lucaciu LA, Constantine-Cooke N, Plevris N, et al. Real-world experience with tofacitinib in ulcerative colitis: A systematic review and meta-analysis. Ther Adv Gastroenterol 2021;14:175628482110640.
Sandborn WJ, Lawendy N, Danese S, et al. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: Final analysis of OCTAVE open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2022;55(4):464–78.
Panaccione R, Abreu MT, Lazariciu I, et al. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: Data from the open-label, long-term extension study, OCTAVE open. Aliment Pharmacol Ther 2022;55(12):1534–44.
Shimizu H, Fujii T, Hibiya S, et al. Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis. Intestinal Res 2021;19(1):115–8.
Hoffmann P, Globig AM, Thomann AK, et al. Tofacitinib in treatment-refractory moderate to severe ulcerative colitis: Real-world experience from a retrospective multicenter observational study. J Clin Med 2020;9(7):2177–13.
Lair-Mehiri L, Stefanescu C, Vaysse T, et al. Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis. Dig Liver Dis 2020;52(3):268–73.
Chaparro M, Garre A, Mesonero F, et al. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry. J Crohns Colitis 2021;15(1):35–42.
Straatmijer T, van Gennep S, Duijvestein M, et al. Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33(10):1288–97.
Honap S, Chee D, Chapman TP, et al. Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: A multicentre UK experience. J Crohns Colitis 2020;14(10):1385–93.
Weisshof R, Golan MA, Sossenheimer PH, et al. Real world experience with tofacitinib in IBD at a tertiary center. Dig Dis Sci 2019;64(7):1945–51.
Biemans VBC, Sleutjes JAM, de Vries AC, et al. Tofacitinib for ulcerative colitis: Results of the prospective Dutch initiative on crohn and colitis (ICC) registry. Aliment Pharmacol Ther 2020;51(9):880–8.
Deepak P, Alayo QA, Khatiwada A, et al. Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis. Clin Gastroenterol Hepatol 2021;19(8):1592–601.e3.
Avni-Biron I, Bar-Gil Shitrit A, Koslowsky B, et al. Short-term effectiveness and safety of tofacitinib in ulcerative colitis–real world data from tertiary medical centers in Israel: Tofacitinib in ulcerative colitis. Dig Liver Dis 2022;54(2):192–7.
Hernández Martínez A, Navajas Hernández P, Martín Rodríguez MdM, et al. Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: Real-life experience in andalusia. Revista Española de Enfermedades Digestivas 2022;114(9):516–21.
Dubinsky MC, Magro F, Steinwurz F, et al. Association of C-reactive protein and partial Mayo score with response to tofacitinib induction therapy: Results from the ulcerative colitis clinical program. Inflamm Bowel Dis 2022:izac061.
Sands BE, Armuzzi A, Marshall JK, et al. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: Results from OCTAVE open. Aliment Pharmacol Ther 2020;51(2):271–80.
Macaluso FS, Maida M, Ventimiglia M, et al. Factors affecting clinical and endoscopic outcomes of placebo arm in trials of biologics and small molecule drugs in ulcerative colitis: A meta-analysis. Inflamm Bowel Dis 2019;25(6):987–97.
Wang Y, Wan Z, Jin R, et al. Tofacitinib for extraintestinal manifestations of inflammatory bowel disease: A literature review. Int Immunopharmacology 2022;105:108517.
Rubin DT, Reinisch W, Greuter T, et al. Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis. Ther Adv Gastroenterol 2021;14:175628482110057.
Rubin DT, Modesto I, Vermeire S, et al. Vermeire|SéverineWorldwide post-marketing safety surveillance experience with tofacitinib in ulcerative colitis. Aliment Pharmacol Ther 2022;55(3):302–10.